Clinical Trial

Impact of Radical Prostatectomy as Primary Treatment in Patients With Prostate Cancer With Limited Bone Metastases

Study acronym: g-RAMPP
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The aim of the study is to investigate, the effect of radical prostatectomy with extended lymphadenectomy on cancer-specific survival, time to castration-resistance, time to progression and quality of life in patients with a limited bone metastatic prostate cancer. In addition the influence of patient- and disease-related factors on clinical outcome (prognostic effect) and on the comparison therapy (predictive effect) will be examined. Amendment05: Due to the slow tumor biology of prostate cancer, the follow-up period of 5 years is not sufficient to reach the primary endpoint of the study. For this reason, the follow-up is extended for a further 5 years with 2 visits per year.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2015-05-22; most recent amendment 2026-01-09.
Status change: Recruiting → Active, Not Recruiting 2019-11-13
Trial Details
NCT Number NCT02454543
Lead Sponsor Martini-Klinik am UKE GmbH
Collaborators: Förderverein Hilfe bei Prostatakrebs e.V.
Conditions Prostate Cancer
Enrollment 452 participants
Start Date 2015-05
Primary Completion 2019-12 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-12